<DOC>
	<DOCNO>NCT01012336</DOCNO>
	<brief_summary>The current recommended guideline patient receive moderately emetogenic chemotherapy ( MEC ) combination 5-HT3 receptor antagonist corticosteroid . Incidence chemotherapy induce nausea vomiting ( CINV ) approximately 50 % patient receive MEC . An incidence rate 25-38 % delayed emesis 55-60 % delay nausea observe . Hence , clearly need effective prevention CINV patient receive MEC , especially woman ovarian carcinoma particularly susceptible symptom . Therefore investigator design study objective evaluate new combination ( Aprepitant/Ramosetron/Dexamethasone ) may improve actual CINV control ovarian carcinoma patient treat taxane/carboplatin .</brief_summary>
	<brief_title>Safety Efficacy Aprepitant , Ramosetron , Dexamethasone Chemotherapy-Induced Nausea Vomiting Patients With Ovarian Cancer Treated With Taxane/Carboplatin</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Aprepitant</mesh_term>
	<mesh_term>Fosaprepitant</mesh_term>
	<mesh_term>Ramosetron</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Taxane</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Inclusion criterion 1. patient 18 year 2. ovarian carcinoma patient treat moderately emetogenic chemotherapy 3 . Karnofsky score &gt; 60 4 . Life expectancy &gt; 4 month Exclusion criteria 1 . Any following condition ( mentally incapacitate emotional psychiatric disorder , user illicit drug , active infection , hypersensitivity ramosetron aprepitant ) 2 . Patients receive nonapproved drug within last 4 week 3. abnormal laboratory value ( AST &gt; 2.5 normal , ALT &gt; 2.5 normal , Bilirubin &gt; 1.5 normal , Creatinine &gt; 1.5 normal ) 4 . Antiemetic drug within 48 hour study 5 . Benzodiazepine opiate within 48 hour 6 . CYP3A4 substrates within 7 day ( terfenadine , cisapride , astemizole , pimozide ) 7 . CYP3A4 inhibitor ( clarithromycin , ketoconazole ) 8 . CYP3A4 inducer within 30 day ( Barbiturates , rifampicin , carbamazepine )</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>efficacy safety Aprepitant/Ramosetron/Dexamethasone ovary cancer patient taxol carboplatin</keyword>
</DOC>